Key takeaways
- McKesson raises its fiscal 2027 earnings outlook after strong Q2 results, fueled by specialty drug demand, operating gains and higher-margin healthcare expansion.
- Stock in this story: MCK. See its latest quote and chart on Trade Conquest.
- Reported by Zacks. Open the full story for every detail.
McKesson raises its fiscal 2027 earnings outlook after strong Q2 results, fueled by specialty drug demand, operating gains and higher-margin healthcare expansion.
See the latest quote, chart and news for MCK.
